Sio Gene Therapies Accounts Payable

Sio Gene Therapies (SIOX) currently reports a accounts payable of $200K as of December 2022. That compares with $6.6M in the prior-year period — down 97.0% year over year. Use the charts on this page to explore Sio Gene Therapies's accounts payable history and peer comparisons.

Sio Gene Therapies's accounts payable decreased from $6.6M to $200K — a 97.0% year-over-year decrease (period ending December 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Sio Gene Therapies reported $200K in accounts payable as of December 2022. That compares with $6.6M in the prior-year period — down 97.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $200K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Sio Gene Therapies, and consider following SIOX for alerts when major investors trade the stock.

Sio Gene Therapies is classified in the Healthcare sector. On accounts payable, it currently shows $200K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SIOX with unrelated industries.